LEADER 06245nam 22007935 450 001 996465421203316 005 20200704194134.0 010 $a3-540-69204-5 024 7 $a10.1007/3-540-63173-9 035 $a(CKB)1000000000234665 035 $a(SSID)ssj0000323026 035 $a(PQKBManifestationID)11243212 035 $a(PQKBTitleCode)TC0000323026 035 $a(PQKBWorkID)10289943 035 $a(PQKB)11526739 035 $a(DE-He213)978-3-540-69204-1 035 $a(PPN)155215582 035 $a(EXLCZ)991000000000234665 100 $a20121227d1997 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt 182 $cc 183 $acr 200 10$aEvolvable Systems: From Biology to Hardware$b[electronic resource] $eFirst International Conference, ICES '96, Tsukuba, Japan, October 7 - 8, 1996, Revised Papers /$fedited by Tetsuya Higuchi, Masaya Iwata, Liu Weixin 205 $a1st ed. 1997. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d1997. 215 $a1 online resource (XIII, 491 p.) 225 1 $aLecture Notes in Computer Science,$x0302-9743 ;$v1259 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-540-63173-9 327 $aIconic learning in networks of logical neurons -- Hardware requirements for fast evaluation of functions learned by Adaptive Logic Networks -- FPGA as a key component for reconfigurable system -- Phylogeny, ontogeny, and epigenesis: Three sources of biological inspiration for softening hardware -- Promises and challenges of Evolvable hardware -- Designing evolware by cellular programming -- Online autonomous evolware -- Speeding-up digital ecologies evolution using a hardware emulator: Preliminary results -- Challenges of evolvable systems: Analysis and future directions -- Functional organisms growing on silicon -- Logical universality and self-reproduction in reversible cellular automata -- Data compression based on Evolvable hardware -- ATM cell scheduling by function level evolvable hardware -- An evolutionary robot navigation system using a gate-level evolvable hardware -- Genetic evolution of a logic circuit which controls an autonomous mobile robot -- Autonomous robot with evolving algorithm based on biological systems -- Memory-based neural network and its application to a mobile robot with evolutionary and experience learning -- Multiple genetic algorithm processor for hardware optimization -- NGEN: A massively parallel reconfigurable computer for biological simulation: Towards a self-organizing computer -- Architecture of cell array neuro-processor -- Special-purpose brainware architecture for data processing -- Evolvable Hardware: An outlook -- Reuse, parameterized reuse, and hierarchical reuse of substructures in evolving electrical circuits using genetic programming -- Machine learning approach to gate-level Evolvable Hardware -- Evolvable systems in hardware design: Taxonomy, survey and applications -- From some tasks to biology and then to hardware -- Adaptive equalization of digital communication channels using Evolvable Hardware -- An evolved circuit, intrinsic in silicon, entwined with physics -- Through the labyrinth evolution finds a way: A silicon ridge -- Hardware evolution system introducing dominant and recessive heredity -- CAM-Brain: A new model for atr's cellular automata based artificial brain project -- Evolution of a 60 decibel op amp using genetic programming -- Evolution of binary decision diagrams for digital circuit design using genetic programming. 330 $aThis book constitutes the strictly refereed post-conference proceedings recording the scientific progress achieved at the First International Conference on Evolvable Systems: From Biology to Hardware, ICES'96, held in Tsukuba, Japan, in October 1996. The volume presents 33 revised full papers including several invited contributions surveying the state of the art in this emerging area of research and development. The volume is divided into topical sections on evolware, cellular systems, engineering applications of evolvable hardware systems, evolutionary robotics, innovative architectures, evolvable systems, evolvable hardware, and genetic programming. 410 0$aLecture Notes in Computer Science,$x0302-9743 ;$v1259 606 $aArtificial intelligence 606 $aArchitecture, Computer 606 $aLogic design 606 $aComputers 606 $aComputer simulation 606 $aBioinformatics  606 $aComputational biology  606 $aArtificial Intelligence$3https://scigraph.springernature.com/ontologies/product-market-codes/I21000 606 $aComputer System Implementation$3https://scigraph.springernature.com/ontologies/product-market-codes/I13057 606 $aLogic Design$3https://scigraph.springernature.com/ontologies/product-market-codes/I12050 606 $aComputation by Abstract Devices$3https://scigraph.springernature.com/ontologies/product-market-codes/I16013 606 $aSimulation and Modeling$3https://scigraph.springernature.com/ontologies/product-market-codes/I19000 606 $aComputer Appl. in Life Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/L17004 615 0$aArtificial intelligence. 615 0$aArchitecture, Computer. 615 0$aLogic design. 615 0$aComputers. 615 0$aComputer simulation. 615 0$aBioinformatics . 615 0$aComputational biology . 615 14$aArtificial Intelligence. 615 24$aComputer System Implementation. 615 24$aLogic Design. 615 24$aComputation by Abstract Devices. 615 24$aSimulation and Modeling. 615 24$aComputer Appl. in Life Sciences. 676 $a621.39/2 702 $aHiguchi$b Tetsuya$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aIwata$b Masaya$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWeixin$b Liu$4edt$4http://id.loc.gov/vocabulary/relators/edt 712 12$aInternational Conference on Evolvable Systems 906 $aBOOK 912 $a996465421203316 996 $aEvolvable Systems: From Biology to Hardware$9772154 997 $aUNISA LEADER 02038oam 2200397 a 450 001 9910701703303321 005 20120912112457.0 035 $a(CKB)5470000002421070 035 $a(OCoLC)805729716 035 $a(EXLCZ)995470000002421070 100 $a20120810d2012 ua 0 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFederal and state structures to support financing utility-scale solar projects and the business models designed to utilize them$b[electronic resource] /$fMichael Mendelsohn and Claire Kreycik 210 1$aGolden, Colo. :$cNational Renewable Energy Laboratory,$d2012. 215 $a1 online resource (x, 41 pages) $ccolor illustrations 225 1 $aNREL/TP ;$v6A20-48685 300 $aTitle from title screen (viewed Aug. 10, 2012). 300 $a"April 2012." 320 $aIncludes bibliographical references (pages 34-41). 330 3 $aUtility-scale solar projects have grown rapidly in number and size over the last few years, driven in part by strong renewable portfolio standards (RPS) and federal incentives designed to stimulate investment in renewable energy technologies. This report provides an overview of such policies, as well as the project financial structures they enable, based on industry literature, publicly available data, and questionnaires conducted by the National Renewable Energy Laboratory (NREL). 606 $aRenewable energy sources$xFinance$xGovernment policy$zUnited States 615 0$aRenewable energy sources$xFinance$xGovernment policy 700 $aMendelsohn$b Michael$01390144 701 $aKreycik$b Claire$01390184 712 02$aNational Renewable Energy Laboratory (U.S.) 801 0$bSOE 801 1$bSOE 801 2$bGPO 906 $aBOOK 912 $a9910701703303321 996 $aFederal and state structures to support financing utility-scale solar projects and the business models designed to utilize them$93483292 997 $aUNINA LEADER 10871nam 22005053 450 001 9911021977103321 005 20250830060330.0 010 $a1-394-20459-0 010 $a1-394-20457-4 010 $a1-394-20458-2 035 $a(CKB)40377778600041 035 $a(MiAaPQ)EBC32272804 035 $a(Au-PeEL)EBL32272804 035 $a(OCoLC)1534811857 035 $a(EXLCZ)9940377778600041 100 $a20250830d2025 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aSecondary Metabolites and Drug Discovery 205 $a1st ed. 210 1$aNewark :$cJohn Wiley & Sons, Incorporated,$d2025. 210 4$d©2025. 215 $a1 online resource (525 pages) 311 08$a1-394-20434-5 327 $aCover -- Series Page -- Title Page -- Copyright Page -- Dedication Page -- Contents -- Preface -- Acknowledgment -- Chapter 1 Drug Discovery and Secondary Metabolites: An Overview -- 1.1 Introduction -- 1.2 Phytochemicals -- 1.3 Secondary Metabolites as Major Resources for Potent Drug Discovery -- 1.4 Conclusion -- Acknowledgment -- References -- Chapter 2 Relationship Between Allopathic Medicine and Secondary Metabolites: Opportunities in Drug Discovery -- 2.1 Introduction -- 2.2 History of Secondary Metabolites -- 2.3 Secondary Metabolites -- 2.3.1 Secondary Metabolites from Plants -- 2.3.2 Biosynthesis of Secondary Metabolites in Plants -- 2.3.3 Secondary Metabolites from Microorganism -- 2.3.3.1 Antibiotics -- 2.3.3.2 Anticancer -- 2.3.4 Secondary Metabolites from Endophytic Microorganisms -- 2.3.4.1 Antibiotics -- 2.3.4.2 Lipopeptides -- 2.3.4.3 Anticancer Agents -- 2.3.4.4 Cyclic Analogs -- 2.3.4.5 Antiviral Agents -- 2.3.4.6 Flavonoids -- 2.3.4.7 Terpenoids and Alkaloids -- 2.4 Modern Techniques Involved in the Production of Secondary Metabolites -- 2.4.1 Manipulation of Secondary Metabolic Clusters' Genetic Control -- 2.4.2 BGCs' Heterogeneous Expression and Refactoring -- 2.4.3 Utilizing Nutrition and Small Molecules -- 2.5 Future Direction and Conclusion -- Acknowledgment -- References -- Chapter 3 Endophytic Microorganisms in Traditional and Modern Plant-Based Medicine: Diversity, Biomedical Applications, and Future Prospects -- 3.1 Introduction -- 3.2 Endophytic Microorganisms in Traditional Plant-Based Medicine -- 3.3 Ayurveda and Indian Traditional Medicine -- 3.3.1 Diversity of Endophytic Microorganisms -- 3.3.2 Medicinal Properties and Uses -- 3.3.2.1 Thespesia populnea -- 3.3.2.2 Datura metel -- 3.3.2.3 Mucuna pruriens -- 3.4 Traditional Chinese Medicine -- 3.4.1 Diversity of Endophytic Microorganism. 327 $a3.4.2 Medicinal Properties and Uses -- 3.4.2.1 Mammals -- 3.4.2.2 Reptiles and Amphibians -- 3.4.2.3 Marine Life -- 3.4.2.4 Plants -- 3.4.2.5 Inorganic Chemicals and Minerals -- 3.5 Immunomodulatory Effects -- 3.6 Cancer Therapeutics -- 3.7 Antibiotic Production -- 3.8 Biotechnological and Agricultural Applications of Endophytic Microorganisms -- 3.8.1 Plant Growth Promotion -- 3.8.2 Biological Control of Plant Pathogens -- 3.8.3 Stress Tolerance -- 3.9 Future Directions for Research and Development -- 3.9.1 Methodological Advances -- 3.9.2 Cultivation-Independent Strategies for Studying Endophytic Fungus -- 3.9.3 Biomedical and Biotechnological Challenges -- 3.9.4 Genomics of Endophytes -- 3.9.5 Bioremediation -- 3.10 Future Research Directions -- 3.11 Conclusion -- References -- Chapter 4 Historical and Current Scenario of Ayurvedic, Unani, and Chinese Medical Systems -- 4.1 History, Present, and Future of Traditional Medicine Techniques -- 4.2 Traditional Chinese Medicine (TCM) -- 4.3 Ayurvedic Medicine -- 4.4 Unani Medicine -- 4.5 Conclusion -- References -- Chapter 5 Historical and Present Scenario of Folklore System of Medicine, Homeopathic System of Medicine -- 5.1 Introduction to Folklore System of Medicine -- 5.1.1 Knowledge Transmission of the Folk Medicine -- 5.1.2 Official and Unofficial Culture -- 5.1.3 Benefits, Risks, and Questions of Efficacy -- 5.1.4 Folk Medicine and Cosmopolitan Medicine -- 5.1.5 Folk Medicine and Modern Medicine -- 5.1.6 Historical Scenario -- 5.1.7 Colonial America -- 5.1.8 Folk Treatments -- 5.1.8.1 Natural Substances -- 5.1.8.2 Physical Therapies -- 5.1.9 Present Scenario -- 5.1.9.1 Women's Health and Folk Medicine -- 5.1.9.2 Interaction with Other Systems -- 5.2 Homeopathic System of Medicine -- 5.2.1 Introduction to Homeopathy -- 5.2.2 Historical Milestones -- 5.2.3 Principal Framework -- 5.2.4 Homeopathy. 327 $a5.2.4.1 Sources -- 5.2.4.2 Preparations -- 5.2.5 Present Status -- 5.2.6 Future Prospect -- 5.3 Conclusion -- Acknowledgement -- References -- Chapter 6 Alternative System of Medicine vs. Traditional System of Medicine -- 6.1 Introduction -- 6.1.1 Traditional Medicinal Practices -- 6.1.2 Complementary and Alternative Medical Care -- 6.2 Contextual -- 6.2.1 Biologically Based Practices -- 6.2.2 Manipulative and Physiological Approaches -- 6.2.3 Mind-Body Medicine -- 6.2.4 Energy-Based Medicine -- 6.2.5 Alternative Medicinal Systems -- 6.3 What is Alternative Medicine? -- 6.4 Different Types of Alternative System of Medicines in India -- 6.4.1 Ayurveda -- 6.4.2 Unani Medicine -- 6.4.3 Homeopathy -- 6.4.4 Siddha -- 6.4.5 Sowa-Ripa -- 6.4.6 Acupuncture -- 6.4.7 Yoga and Naturopathy -- 6.4.8 Other Alternative Modalities -- 6.4.8.1 Chiropractic Medicine -- 6.4.8.2 Herbal Medicine -- 6.4.8.3 Mind-Body Therapies -- 6.4.8.4 Biologically Based Practices -- 6.4.8.5 Some Commonly Used Herbal Supplements -- 6.4.8.6 Manipulative and Body-Based Practices -- 6.4.8.7 Energy Healing -- 6.5 Future Scope of Traditional Medicine -- 6.6 Traditional Indian Medicine History -- 6.7 Development of Traditional Indian Medicine -- 6.7.1 Overall System of Management -- 6.7.2 Policy -- 6.7.3 Education -- 6.7.4 Medical Treatment -- 6.7.5 Drugs -- 6.7.6 Scientific Research -- 6.7.7 Industry -- 6.7.8 Intellectual Property Protection -- 6.7.9 Pharmacovigilance System -- 6.8 Why People Use Alternative Medicines? -- 6.8.1 National Policy and Regulation -- 6.8.2 Safety, Efficacy, and Quality -- 6.8.3 Access -- 6.8.4 Rational Use -- 6.9 Alternative Medicine and Its Importance -- 6.9.1 Challenges -- 6.9.2 Initiatives for AYUSH Promotion -- 6.9.3 Measures to be Taken for Integrating AYUSH -- 6.9.4 However, Prerequisites of Such Integration Need Substantial Groundwork. 327 $a6.10 Global Use of Traditional Medicine -- 6.10.1 Diagnosis in Ayurveda -- 6.10.2 Treatment in Ayurveda -- 6.10.3 Ayurveda Characteristics -- 6.10.4 Advantages of Clinical Treatment -- 6.11 Conclusion -- References -- Chapter 7 Cost, Benefits, and Side Effects of Alternative, Complementary, and Traditional Medicine to Control Non-Communicable Diseases -- 7.1 Introduction -- 7.1.1 Costs of ACTM for NCDs -- 7.1.1.1 Direct Costs of ACTM -- 7.1.1.2 Indirect Costs of ACTM -- 7.1.2 ACTM for NCDs: The Cost Beyond the Dollar -- 7.1.2.1 Financial Cost Transparency -- 7.1.2.2 Insurance Coverage and Cost Sharing -- 7.1.2.3 Cost-Effectiveness Analysis -- 7.1.2.4 Societal Cost Considerations -- 7.2 Benefits of ACTM for NCDs -- 7.2.1 Reduced Side Effects -- 7.2.2 Holistic Approach to Health -- 7.2.3 Patient-Centered Care -- 7.2.4 Psychological Well-Being -- 7.2.5 Potential Benefits for Specific NCDs -- 7.3 Holistic Approach to Health Management -- 7.4 Side Effects and Risks of ACTM for NCDs -- 7.4.1 Potential for Adverse Reactions -- 7.4.2 Interactions with Conventional Medicine -- 7.4.3 Strategies for Mitigating Risks -- 7.4.4 Encourage Open Communication and Disclosure -- 7.4.5 Educate Patients and Healthcare Providers -- 7.4.6 Ensure Practitioner Qualifications -- 7.4.7 Implement Safety and Quality Standards -- 7.4.8 Utilize Technology for Monitoring and Management -- 7.4.9 Adopt a Holistic and Personalized Approach -- 7.5 Comparative Analysis: ACTM vs. Conventional Medicine for NCDs -- 7.5.1 Prevalence and Utilization -- 7.5.2 Patient Satisfaction -- 7.5.3 Safety Concerns -- 7.5.4 Systems Medicine and Integrated Care -- 7.5.5 Coverage and Evidence Development -- 7.5.6 Determinants of CAM Use -- 7.6 Integration and Considerations of ACTMs for NCDs -- 7.7 Conclusions -- Acknowledgements -- References -- Chapter 8 Integrative Medicine: An Overview. 327 $a8.1 Introduction -- 8.2 Overview of Integrative Medicine -- 8.3 Current Contributions -- 8.4 Integrative Vision of Healthcare-Public Health: Policy and Recommendations -- 8.5 Benefits of Integrative Medicine -- 8.6 Integrative Mental Health -- 8.7 Integrative Medicine for the Underserved -- 8.8 Philosophy of Integrative Medicine -- 8.9 Relationship-Centered Care -- 8.10 Prevention -- 8.11 Integration -- 8.12 Conclusion -- Acknowledgment -- References -- Chapter 9 Different Sources and Types of Drug Molecules Used in Homeopathy System of Medicine -- 9.1 Introduction -- 9.2 Brief History of Homeopathy -- 9.3 Homeopathy System of Medicine -- 9.4 The Art and Science of Drugs in Homeopathy -- 9.5 Source and Types of Drug Molecules Used in Homeopathic System of Medicine -- 9.5.1 Plant Kingdom -- 9.5.2 Animal Kingdom -- 9.5.3 Mineral Kingdom -- 9.5.4 Sarcodes -- 9.5.5 Nosodes -- 9.5.6 Imponderabilia -- 9.5.7 Synthetic Sources of Some Drugs -- 9.6 Criticism on Homeopathic System of Medicine -- 9.7 Limitation of Drug Molecules Used in Homeopathy -- 9.8 Future Direction and Drug Discovery -- 9.9 Conclusion -- Acknowledgement -- References -- Chapter 10 Cost, Benefits, and Side Effects of Allopathic Medicine to Control Communicable Diseases -- 10.1 Background -- 10.2 Etiopathogenesis of Common Communicable Diseases -- 10.2.1 Viral Communicable Disease -- 10.2.2 Bacterial Communicable Diseases -- 10.2.3 Etiopathogenesis of Non-Viral and Non-Bacterial Communicable Diseases -- 10.3 Sign and Symptoms of Communicable Disease -- 10.4 Mode of Transmission of Communicable Diseases -- 10.5 Preventive Measures of Communicable Diseases -- 10.6 Cost and Benefit of Current Allopathic Medicine for the Treatment of Communicable Diseases -- 10.7 Side Effects of Allopathic Medicine to Control Communicable Diseases -- 10.7.1 Tuberculosis -- 10.7.2 Malaria -- 10.7.3 Cholera. 327 $a10.7.4 Measles. 330 $aThis book explores the promising potential of plant and microbe-derived compounds in drug discovery, offering insights into safer alternatives to synthetic drugs and highlighting the vital role of natural products in treating diseases with fewer side effects. 676 $a615.19 700 $aDar$b Umar Ali$01837359 701 $aShahnawaz$b Mohd$0872809 701 $aSingh$b Neha$01280228 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911021977103321 996 $aSecondary Metabolites and Drug Discovery$94429239 997 $aUNINA LEADER 05316nam 22007455 450 001 9910349272903321 005 20251113184526.0 010 $a3-030-32281-5 024 7 $a10.1007/978-3-030-32281-6 035 $a(CKB)4100000009522969 035 $a(DE-He213)978-3-030-32281-6 035 $a(MiAaPQ)EBC5940981 035 $a(PPN)248601636 035 $a(EXLCZ)994100000009522969 100 $a20191010d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPredictive Intelligence in Medicine $eSecond International Workshop, PRIME 2019, Held in Conjunction with MICCAI 2019, Shenzhen, China, October 13, 2019, Proceedings /$fedited by Islem Rekik, Ehsan Adeli, Sang Hyun Park 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (XIII, 178 p. 58 illus., 48 illus. in color.) 225 1 $aImage Processing, Computer Vision, Pattern Recognition, and Graphics,$x3004-9954 ;$v11843 311 08$a3-030-32280-7 327 $aTADPOLE Challenge: Accurate Alzheimer's disease prediction through crowdsourced forecasting of future data -- Inter-fractional Respiratory Motion Modelling from Abdominal Ultrasound: A Feasibility Study -- Adaptive Neuro-Fuzzy Inference System-based Chaotic Swarm Intelligence Hybrid Model for Recognition of Mild Cognitive Impairment from Resting-state fMRI -- Deep Learning via Fused Bidirectional Attention Stacked Long Short-term Memory for Obsessive-Compulsive Disorder Diagnosis and Risk Screening -- Modeling Disease Progression In Retinal OCTs With Longitudinal Self-Supervised Learning -- Predicting Response to the Antidepressant Bupropion using Pretreatment fMRI -- Progressive Infant Brain Connectivity Evolution Prediction from Neonatal MRI using Bidirectionally Supervised Sample Selection -- Computed Tomography Image-Based Deep Survival Regression for Metastatic Colorectal Cancer using a Non-Proportional Hazards Model -- 7 years of Developing Seed Techniques for Alzheimer's Disease Diagnosis using Brain Image and Connectivity Data Largely Bypassed Prediction for Prognosis -- Generative Adversarial Irregularity Detection in Mammography Images -- Hierarchical Adversarial Connectomic Domain Alignment for Target Brain Graph Prediction and Classification From a Source Graph -- Predicting High-Resolution Brain Networks Using Hierarchically Embedded and Aligned Multi-Resolution Neighborhoods -- Catheter Synthesis in X-Ray Fluoroscopy with Generative Adversarial Networks -- Prediction of Clinical Scores for Subjective Cognitive Decline and Mild Cognitive Impairment -- Diagnosis of Parkinsons Disease in Genetic Cohort Patients via Stage-wise Hierarchical Deep Polynomial Ensemble learning -- Automatic Detection of Bowel Disease with Residual Networks -- Support Vector based Autoregressive Mixed Models of Longitudinal Brain Changes and Corresponding Genetics in Alzheimers Disease -- Treatment Response Prediction of Hepatocellular Carcinoma Patients from Abdominal CT Images with Deep Convolutional Neural Networks. 330 $aThis book constitutes the proceedings of the Second International Workshop on Predictive Intelligence in Medicine, PRIME 2019, held in conjunction with MICCAI 2019, in Shenzhen, China, in October 2019. The 18 papers presented in this volume were carefully reviewed and selected for inclusion in this book. The contributions describe new cutting-edge predictive models and methods that solve challenging problems in the medical field for a high-precision predictive medicine. . 410 0$aImage Processing, Computer Vision, Pattern Recognition, and Graphics,$x3004-9954 ;$v11843 606 $aArtificial intelligence 606 $aComputer science$xMathematics 606 $aMathematical statistics 606 $aImage processing$xDigital techniques 606 $aComputer vision 606 $aAlgorithms 606 $aData mining 606 $aArtificial Intelligence 606 $aProbability and Statistics in Computer Science 606 $aComputer Imaging, Vision, Pattern Recognition and Graphics 606 $aAlgorithms 606 $aData Mining and Knowledge Discovery 615 0$aArtificial intelligence. 615 0$aComputer science$xMathematics. 615 0$aMathematical statistics. 615 0$aImage processing$xDigital techniques. 615 0$aComputer vision. 615 0$aAlgorithms. 615 0$aData mining. 615 14$aArtificial Intelligence. 615 24$aProbability and Statistics in Computer Science. 615 24$aComputer Imaging, Vision, Pattern Recognition and Graphics. 615 24$aAlgorithms. 615 24$aData Mining and Knowledge Discovery. 676 $a610.28563 676 $a610.28563 702 $aRekik$b Islem$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aAdeli$b Ehsan$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aPark$b Sang Hyun$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910349272903321 996 $aPredictive Intelligence in Medicine$92569032 997 $aUNINA